Harpoon Therapeutics, Inc. (NASDAQ:HARP) Major Shareholder Sells $7,385,107.12 in Stock

Harpoon Therapeutics, Inc. (NASDAQ:HARP) major shareholder Impact Fund (Cayman) Oncology sold 328,519 shares of the business’s stock in a transaction dated Tuesday, May 4th. The shares were sold at an average price of $22.48, for a total value of $7,385,107.12. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Impact Fund (Cayman) Oncology also recently made the following trade(s):

  • On Thursday, April 29th, Impact Fund (Cayman) Oncology sold 130,143 shares of Harpoon Therapeutics stock. The shares were sold at an average price of $21.99, for a total transaction of $2,861,844.57.

Shares of NASDAQ HARP traded down $0.05 during midday trading on Tuesday, reaching $23.20. The stock had a trading volume of 398,285 shares, compared to its average volume of 277,394. The company’s 50 day moving average price is $20.69 and its 200 day moving average price is $18.31. Harpoon Therapeutics, Inc. has a twelve month low of $10.55 and a twelve month high of $25.24. The firm has a market cap of $751.94 million, a price-to-earnings ratio of -10.89 and a beta of 0.87.

Harpoon Therapeutics (NASDAQ:HARP) last issued its quarterly earnings results on Tuesday, March 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.09. The firm had revenue of $7.49 million for the quarter, compared to analyst estimates of $4.92 million. Harpoon Therapeutics had a negative return on equity of 68.32% and a negative net margin of 434.74%. On average, equities research analysts expect that Harpoon Therapeutics, Inc. will post -2.12 earnings per share for the current year.

A number of analysts have recently weighed in on the stock. SVB Leerink cut their price target on shares of Harpoon Therapeutics from $31.00 to $29.00 and set an “outperform” rating for the company in a report on Wednesday, March 17th. Robert W. Baird restated a “buy” rating and set a $35.00 target price on shares of Harpoon Therapeutics in a research note on Monday, March 22nd. Finally, Zacks Investment Research downgraded shares of Harpoon Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 15th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Harpoon Therapeutics presently has an average rating of “Buy” and an average target price of $30.78.

Large investors have recently bought and sold shares of the company. US Bancorp DE raised its holdings in shares of Harpoon Therapeutics by 42.1% in the 4th quarter. US Bancorp DE now owns 1,705 shares of the company’s stock worth $28,000 after acquiring an additional 505 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in Harpoon Therapeutics during the 3rd quarter worth approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Harpoon Therapeutics during the 1st quarter worth approximately $50,000. Pura Vida Investments LLC purchased a new stake in shares of Harpoon Therapeutics in the fourth quarter worth approximately $169,000. Finally, Citigroup Inc. lifted its holdings in shares of Harpoon Therapeutics by 31.6% in the fourth quarter. Citigroup Inc. now owns 11,988 shares of the company’s stock valued at $199,000 after purchasing an additional 2,880 shares in the last quarter. 79.03% of the stock is owned by institutional investors.

About Harpoon Therapeutics

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Insider Buying and Selling by Quarter for Harpoon Therapeutics (NASDAQ:HARP)

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.